The Technical Analyst
Vaxcyte Inc [PCVX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Vaxcyte Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.90% $60.62
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6 571.69 mill |
| EPS: | -4.14 |
| P/E: | -14.64 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 108.41 mill |
| Avg Daily Volume: | 0.842 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -14.64 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.49x |
| Company: PE -14.64 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.79 (-93.75%) $-56.83 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 58.15 - 63.09 ( +/- 4.07%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Eydelman Mikhail | Sell | 1 667 | Stock Option (right to buy) |
| 2024-04-01 | Eydelman Mikhail | Buy | 1 667 | Common Stock |
| 2024-04-01 | Eydelman Mikhail | Sell | 1 397 | Common Stock |
| 2024-04-01 | Eydelman Mikhail | Sell | 270 | Common Stock |
| 2024-04-01 | Wassil Jim | Sell | 2 323 | Common Stock |
| INSIDER POWER |
|---|
| 40.84 |
| Last 100 transactions |
| Buy: 791 917 | Sell: 331 806 |
Forecast:
16:00 - $60.62
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $60.62
Forecast 2: 16:00 - $60.62
Forecast 3: 16:00 - $60.62
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $60.62 (-2.90% ) |
| Volume | 0.634 mill |
| Avg. Vol. | 0.842 mill |
| % of Avg. Vol | 75.39 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PCVX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $74.00 | N/A | Active |
|---|
PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Latest Press Releases
2024-04-02 16:05:00 - Press Release
Vaxcyte To Present At The 23rd Annual Needham Virtual Healthcare Conference
San carlos, calif., april 02, 2024 (globe newswire) -- vaxcyte, inc. (nasdaq: pcvx), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that company management will participate in a fireside chat at the 23rd annual needham virtual healthcare conference on tuesday, april 9 at 12:45 p.m. et / 9:45 a.m. pt.
2024-03-04 08:30:00 - Press Release
Vaxcyte Completes Enrollment Of Phase 2 Study Evaluating Vax-24 For The Prevention Of Invasive Pneumococcal Disease (ipd) In Infants
-- company expects to announce topline safety, tolerability and immunogenicity data from primary immunization series by the end of the first quarter of 2025, followed by topline data from booster dose by the end of 2025 -- -- vax-24, a 24-valent pneumococcal conjugate vaccine (pcv), is designed to cover more serotypes than any infant pneumococcal vaccine on-market or in u.s. clinics today --
2024-02-27 16:01:00 - Press Release
Vaxcyte Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
-- vax-31 adult program phase 1/2 study enrollment complete; topline safety, tolerability and immunogenicity data expected in third quarter of 2024 -- -- completed successful vax-24 phase 2 adult program and end-of-phase 2 meeting; vax-24 is phase 3-ready in adults --
2024-02-15 16:05:00 - Press Release
Vaxcyte To Report Fourth Quarter And Full Year 2023 Financial Results On February 27, 2024
San carlos, calif., feb. 15, 2024 (globe newswire) -- vaxcyte, inc. (nasdaq: pcvx), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on february 27, 2024. company management will host a conference call and webcast beginning at 4:30 p.m. et / 1:30 p.m. pt that day to discuss the financial results and provide a business update.
2024-02-02 18:39:00 - Press Release
Vaxcyte Announces Closing Of $862.5 Million Public Offering Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
San carlos, calif., feb. 02, 2024 (globe newswire) -- vaxcyte, inc. (nasdaq: pcvx), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,695,312 shares of common stock at a public offering price of $64.00 per share and pre-funded warrants to purchase 781,250 shares of common stock at a public offering price of $63.999 per underlying share. this includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions...
Latest News
2024-04-02 16:05:00 - GlobeNewsWire
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT.
2024-02-28 13:01:08 - Zacks Investment Research
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-02-26 09:36:06 - Zacks Investment Research
Why Vaxcyte (PCVX) Might Surprise This Earnings Season
Vaxcyte (PCVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2024-02-26 08:41:06 - Zacks Investment Research
5 Stocks to Buy That Are Poised to Beat on Earnings This Week
We have narrowed our search to five stocks that are poised to beat on earnings this week. These are: HEi, CEG, IPAR, APLS, PCVX.
2024-02-15 16:05:00 - GlobeNewsWire
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.
2024-02-01 16:05:00 - GlobeNewsWire
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on Thursday, February 8, 2024 at 10:00 a.m. ET / 7:00 a.m. PT.
2023-10-31 16:05:00 - GlobeNewsWire
Vaxcyte to Present at Upcoming Investor Conferences
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences:
2023-09-19 16:05:00 - GlobeNewsWire
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
SAN CARLOS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023 at 11:40 a.m. ET / 8:40 a.m. PT.
2023-08-17 18:34:35 - Seeking Alpha
Strong Financials And Pipeline Position Vaxcyte For Success
Vaxcyte, Inc. is a clinical-stage vaccine company developing high-fidelity vaccines for bacterial diseases. The company's Q2 2023 earnings report shows significant growth in cash and investments, indicating a solid liquidity position. Positive Phase 2 data for Vaxcyte's VAX-24 vaccine and a promising pipeline make it a recommended speculative "Buy" for investors.
2023-06-13 10:32:12 - Zacks Investment Research
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.